293 related articles for article (PubMed ID: 29549242)
1. SUMO targets the APC/C to regulate transition from metaphase to anaphase.
Eifler K; Cuijpers SAG; Willemstein E; Raaijmakers JA; El Atmioui D; Ovaa H; Medema RH; Vertegaal ACO
Nat Commun; 2018 Mar; 9(1):1119. PubMed ID: 29549242
[TBL] [Abstract][Full Text] [Related]
2. Sumoylation promotes optimal APC/C Activation and Timely Anaphase.
Lee CC; Li B; Yu H; Matunis MJ
Elife; 2018 Mar; 7():. PubMed ID: 29517484
[TBL] [Abstract][Full Text] [Related]
3. Sumoylation of Kif18A plays a role in regulating mitotic progression.
Yang F; Chen Y; Dai W
BMC Cancer; 2015 Mar; 15():197. PubMed ID: 25884224
[TBL] [Abstract][Full Text] [Related]
4. SUMO-2/3 regulates topoisomerase II in mitosis.
Azuma Y; Arnaoutov A; Dasso M
J Cell Biol; 2003 Nov; 163(3):477-87. PubMed ID: 14597774
[TBL] [Abstract][Full Text] [Related]
5. Converging Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Signaling: Improved Methodology Identifies Co-modified Target Proteins.
Cuijpers SAG; Willemstein E; Vertegaal ACO
Mol Cell Proteomics; 2017 Dec; 16(12):2281-2295. PubMed ID: 28951443
[TBL] [Abstract][Full Text] [Related]
6. RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response.
Poulsen SL; Hansen RK; Wagner SA; van Cuijk L; van Belle GJ; Streicher W; Wikström M; Choudhary C; Houtsmuller AB; Marteijn JA; Bekker-Jensen S; Mailand N
J Cell Biol; 2013 Jun; 201(6):797-807. PubMed ID: 23751493
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
8. Smt3/SUMO and Ubc9 are required for efficient APC/C-mediated proteolysis in budding yeast.
Dieckhoff P; Bolte M; Sancak Y; Braus GH; Irniger S
Mol Microbiol; 2004 Mar; 51(5):1375-87. PubMed ID: 14982631
[TBL] [Abstract][Full Text] [Related]
9. Mps1 is SUMO-modified during the cell cycle.
Restuccia A; Yang F; Chen C; Lu L; Dai W
Oncotarget; 2016 Jan; 7(3):3158-70. PubMed ID: 26675261
[TBL] [Abstract][Full Text] [Related]
10. RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin.
Klein UR; Haindl M; Nigg EA; Muller S
Mol Biol Cell; 2009 Jan; 20(1):410-8. PubMed ID: 18946085
[TBL] [Abstract][Full Text] [Related]
11. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis.
Zhang XD; Goeres J; Zhang H; Yen TJ; Porter AC; Matunis MJ
Mol Cell; 2008 Mar; 29(6):729-41. PubMed ID: 18374647
[TBL] [Abstract][Full Text] [Related]
12. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation regulates polo-like kinase 1-interacting checkpoint helicase (PICH) during mitosis.
Sridharan V; Park H; Ryu H; Azuma Y
J Biol Chem; 2015 Feb; 290(6):3269-76. PubMed ID: 25564610
[TBL] [Abstract][Full Text] [Related]
14. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
15. SUMO chains: polymeric signals.
Vertegaal AC
Biochem Soc Trans; 2010 Feb; 38(Pt 1):46-9. PubMed ID: 20074033
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.
Higginbotham JM; O'Shea CC
J Virol; 2015 Oct; 89(20):10260-72. PubMed ID: 26223632
[TBL] [Abstract][Full Text] [Related]
17. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
20. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
